Gong X-J, Song X-Y, Wei H, Wang J, Niu M
Department of Emergency Internal Medicine, the Affiliated Hospital of Qingdao University, Qingdao, China.
Eur Rev Med Pharmacol Sci. 2015 Jun;19(12):2221-5.
Myocardial infarction causes significant mortality and morbidity. Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. Biomarkers have been used to assist with timely diagnosis, while an increasing number of novel markers have been identified to predict outcome following an acute myocardial infarction or acute coronary syndrome. The objective of this study was to determine S100A4 expression in AMI and determine whether S100A4 could be a biomarker for detection of acute myocardial infarction (AMI).
We measured circulating S100A4 levels in 173 patients (median age 58.3 years) who presented with first-time AMI 8 hours after the incident. The circulating S100A4 levels in 173 healthy volunteers (median age 57.3 years) was also measured. S100A4 was detected using enzyme immunoassay in both groups.
Serum S100A4 levels were significantly higher in patients with AMI [89.6 (4.3-214.6) pg/ml] compared to controls [11.8 (0-41.5) pg/ml] (p < 0.001). We found that a S100A4 level > 41.5 pg/ml had a Sensitivity 76.3% and specificity 87.5% for predicting AMI. S100A4 revealed the higher sensitivity for diagnosing AMI.
Elevated S100A4 in plasma may be a novel biomarker for early detection of AMI.
心肌梗死会导致严重的死亡率和发病率。及时诊断可让临床医生对患者进行风险分层并选择合适的治疗方法。生物标志物已被用于辅助及时诊断，同时越来越多的新型标志物已被确定可预测急性心肌梗死或急性冠状动脉综合征后的预后。本研究的目的是确定急性心肌梗死（AMI）中S100A4的表达，并确定S100A4是否可作为检测急性心肌梗死（AMI）的生物标志物。
我们测量了173例首次发生急性心肌梗死且发病8小时后的患者（中位年龄58.3岁）的循环S100A4水平。还测量了173名健康志愿者（中位年龄57.3岁）的循环S100A4水平。两组均采用酶免疫法检测S100A4。
与对照组[11.8（0 - 41.5）pg/ml]相比，急性心肌梗死患者的血清S100A4水平显著更高[89.6（4.3 - 214.6）pg/ml]（p < 0.001）。我们发现，S100A4水平> 41.5 pg/ml对预测急性心肌梗死的敏感性为76.3%，特异性为87.5%。S100A4对诊断急性心肌梗死显示出更高的敏感性。
血浆中S100A4升高可能是早期检测急性心肌梗死的一种新型生物标志物。
